CPI-0610 is a novel BET (bromodomain and extra-terminal) inhibitor that is currently being studied in clinical trials for the treatment of various hematological malignancies, including myelofibrosis, acute myeloid leukemia (AML), and lymphoma. CPI-0610 works by inhibiting the function of BRD4 and other BET proteins, which play a crucial role in the regulation of gene expression.
Chemical Name:
The chemical name for CPI-0610 is (S)-N-(4-(3-(4-chloro-1-(2-methyl-4-(piperidin-1-yl)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yl)phenyl)piperidin-1-yl)propane-1-sulfonamide.
Molecular Formula:
The molecular formula for CPI-0610 is C34H43ClN8O2S.
Formula Weight:
The formula weight for CPI-0610 is 671.24 g/mol.
CAS No:
The CAS number for CPI-0610 is 1380087-89-7.
Top Ten Keywords from Google and Synonyms:
Synonyms:
Health Benefits of this Product:
CPI-0610 has shown promising health benefits in various preclinical and clinical studies. Some of the potential health benefits are discussed below.
Anticancer Effects: CPI-0610 has potent anticancer effects that have been demonstrated in various types of cancers, including hematological malignancies like myelofibrosis, AML, and lymphoma. It inhibits the function of BRD4, which is overexpressed in many cancers, leading to the dysregulation of oncogenes and tumor suppressor genes. By inhibiting BRD4, CPI-0610 reduces cancer cell growth, induces apoptosis, and enhances the effectiveness of chemotherapy.
Anti-inflammatory Effects: CPI-0610 has anti-inflammatory effects that can reduce inflammation in various inflammatory diseases like rheumatoid arthritis and psoriasis. It inhibits the production of pro-inflammatory cytokines like interleukin-6 (IL-6) and interleukin-1 beta (IL-1β).
Potential Effects:
Apart from the above-discussed health benefits, CPI-0610 has several other potential effects that are being studied.
Neuroprotective Effects: CPI-0610 may have neuroprotective effects by reducing oxidative stress and inflammation in the brain. It also enhances synaptic plasticity and improves cognitive function in animal models of neurodegenerative diseases.
Cardioprotective Effects: CPI-0610 may have cardioprotective effects by reducing oxidative stress and inflammation in the heart. It also improves cardiac function and decreases infarct size in experimental myocardial infarction.
Product Mechanism:
CPI-0610 exerts its biological effects by binding to the bromodomain of BRD4 and blocking its function. BRD4 is a transcriptional regulator that plays a crucial role in the regulation of gene expression. By inhibiting BRD4, CPI-0610 reduces the expression of genes that promote cancer cell growth and survival and increases the expression of genes that induce apoptosis and inhibit metastasis.
Safety:
CPI-0610 is generally safe to use when administered under medical supervision. However, it may cause adverse effects like fatigue, nausea, vomiting, anemia, and thrombocytopenia. It may also increase the risk of infections and bleeding. Therefore, patients receiving CPI-0610 should be monitored regularly for any signs of adverse effects.
Dosing Information:
The dosing information for CPI-0610 varies depending on the type of cancer being treated and the patient's medical history. The drug is administered orally once or twice daily at a dose ranging from 100 to 400 mg. The dosage may be adjusted based on the patient's response to treatment and the occurrence of adverse effects.
